Filing Flows

Filing Flows › Tandem Diabetes Care (TNDM) › Next earnings date

Tandem Diabetes Care (TNDM) earnings: beat the estimate

Tandem Diabetes Care (TNDM) reported on Nov 5, 2026 and beat the EPS estimate: −$0.10 against −$0.24 (+58.4%). Revenue was $284M for Q3 2026, +14% year over year. The stock moved -10.4% on the report. It beat the EPS estimate in 100% of the quarters on record.

Last result+58.4% vs estimate
Beat rate100%

The last report

Tandem Diabetes Care reported revenue of $284M for the third quarter 2026 (+14% Y/Y), net loss $7.1M: Supplies and other $169M, Pump $115M. How it makes money → · Every quarter →

Tandem Diabetes Care: EPS against the estimate, last 5 reportsTandem Diabetes Care: EPS against the estimate, last 5 reportsEstimateReported−$0.34−$0.31Nov 25−$0.09−$0.01Feb 26−$0.44−$0.30May 26−$0.32−$0.31Aug 26−$0.24−$0.10Nov 26
Latest (Nov 26): Estimate −$0.24, Reported −$0.10.
TNDM: the stock's move on each reportTNDM: the stock's move on each reportNov 5, 2026-10.4%Aug 6, 2026+14.2%May 7, 2026-14.1%Feb 19, 2026+29.7%Nov 6, 2025+10.8%

Tandem Diabetes Care's latest quarter

Tandem Diabetes Care, Q3 2026: revenue $284M (+14% year over year), operating margin -0.8%, net loss $7.1M, operating cash flow −$819K. The chart follows the revenue to costs, profit and cash.

Questions

Did Tandem Diabetes Care beat earnings?

Tandem Diabetes Care (TNDM) reported on Nov 5, 2026 and beat the EPS estimate: −$0.10 against −$0.24 (+58.4%).

When does TNDM report earnings?

The next date is not set yet.

Does Tandem Diabetes Care usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.